Disclosed on December 18, Amir Weiss, Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE:TEVA), executed a substantial insider sell as per the latest SEC filing.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Thursday outlined that Weiss executed a sale of 12,300 shares of Teva Pharmaceutical Indus with a total value of $371,504.
Monitoring the market, Teva Pharmaceutical Indus's shares down by 1.15% at $29.97 during Friday's morning.
<h3>Get to Know Teva Pharmaceutical Indus Better</h3>
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Teva Pharmaceutical Indus: Financial Performance Dissected</h3>
Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 3.42% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 51.43%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Teva Pharmaceutical Indus's EPS reflects a decline, falling below the industry average with a current EPS of 0.38.
</li>
</ul>
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio stands notably higher than the industry average, reaching 2.35. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 49.7 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 2.08 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 17.31, Teva Pharmaceutical Indus could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
<h3>Why Pay Attention to Insider Transactions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
Exploring the legal landscape, an &#34;insider&#34; is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Surveying the realm of stock transactions, investors often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Teva Pharmaceutical Indus's Insider Trades.
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. Click here for access.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TEVA

Amir Weiss, Chief Accounting Officer at Teva Pharmaceutical Indus, sold 12,300 shares worth $371,504, as disclosed in a Form 4 filing with the SEC. Teva's shares fell 1.15% to $29.97. Teva, a leading generic drug manufacturer, faces financial challenges with low gross margin and high debt-to-equity ratio. Despite undervaluation indicators, insider transactions should be considered alongside other investment factors.

Insider Selling: Amir Weiss Unloads $371K Of Teva Pharmaceutical Indus Stock